Arriving in the landscape of obesity management, retatrutide is a unique method. Unlike many existing medications, retatrutide works as a double agonist, concurrently engaging both GLP-like peptide-1 (GLP-1) and glucose-dependent insulinotropic hormone (GIP) binding sites. This concurrent stimulation fosters various advantageous effects, including